✦ LIBER ✦

Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the United Kingdom

✍ Scribed by S. Morris; S. Ridley; V. Munro; M. C. Christensen; the NovoSeven® Trauma Study Group

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness of Recombinant Activa

✍ Rolf Rossaint; Michael C. Christensen; Philip Iau Tsau Choong; Kenneth D. Boffar 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB

The use of recombinant activated Factor

✍ A. Udy; M. Vaghela; G. Lawton; P. Sigston 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

Cost effectiveness of drotrecogin alfa (

✍ A. Davies; S. Ridley; J. Hutton; C. Chinn; B. Barber; D. C. Angus 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

A response to ‘The use of recombinant ac

✍ J. Geoghegan; L. Tasker 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 48 KB

The Cost-Effectiveness of Bosentan in th

✍ Matt D. Stevenson; Frances C. Macdonald; Jonathan Langley; Elke Hunsche; Ron Ake 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

The use of activated recombinant coagula

✍ R. González-Boullosa; R. Ocampo-Martínez; M. J. Alarcón-Martín; M. Suárez-Rodríg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB